For personal use only
Appendix 3Y
Change of Director's Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity | Anatara Lifesciences Limited |
ABN | 41 145 239 872 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director | David Brookes |
Date of last notice | 4 December 2020 |
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest | Direct & Indirect |
Nature of indirect interest | Indirect - David & Elisabeth Brookes atf Dr |
(including registered holder) | DL Brookes Personal Superfund |
Note: Provide details of the circumstances giving rise to the relevant | |
interest. | |
Date of change | 9 December 2021 |
No. of securities held prior to change | Indirect - David & Elisabeth Brookes atf Dr |
DL Brookes Personal Superfund 300,000 | |
Ordinary Shares & | |
65,658 Options with an exercise price of | |
$0.2476 and expire on 3 December 2022 | |
Class | Options |
Number acquired | Direct: |
900,000 at $0.225 ea; vesting 450,000 16 | |
November 2022 & 450,000 16 November | |
2023; expire 14 November 2025 | |
Number disposed | Nil |
Value/Consideration | Nil |
Note: If consideration is non-cash, provide details and estimated | |
valuation | |
- See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1
For personal use only
Appendix 3Y
Change of Director's Interest Notice
No. of securities held after change | Direct: | ||
900,000 at $0.225 ea; vesting 450,000 16 | |||
November 2022 & 450,000 16 November | |||
2023; expire 14 November 2025 | |||
Indirect - David & Elisabeth Brookes atf Dr | |||
DL Brookes Personal Superfund 300,000 | |||
Ordinary Shares & | |||
65,658 Options with | an exercise price | of | |
$0.2476 and expire on 3 December 2022 | |||
Nature of change | |||
Example: on-market trade, off-market trade, exercise of options, | The issued Options | were approved | by |
issue of securities under dividend reinvestment plan, participation in | |||
Shareholders at the Annual General Meeting | |||
buy-back | |||
held on 16 November 2021 | |||
Part 2 - Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract | Nil |
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change
Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
Part 3 - +Closed period
Were the interests in the securities or contracts detailed N/A above traded during a +closed period where prior written clearance was required?
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 | 01/01/2011 |
For personal use only
Appendix 3Y
Change of Director's Interest Notice
If so, was prior written clearance provided to allow the trade | N/A |
to proceed during this period? | |
If prior written clearance was provided, on what date was this | N/A |
provided? | |
- See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3
For personal use only
Appendix 3Y
Change of Director's Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity | Anatara Lifesciences Limited |
ABN | 41 145 239 872 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director | Sue MacLeman |
Date of last notice | 13 September 2021 |
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest | Indirect |
Nature of indirect interest | N/A |
(including registered holder) | |
Note: Provide details of the circumstances giving rise to the relevant | |
interest. | |
Date of change | 9 December 2021 |
No. of securities held prior to change | Indirect - Dalroar Pty Ltd (MacLeman |
Investment Trust) 78,069 Ordinary Shares & | |
122,548 Options with an exercise price of | |
$0.2476 and expire on 3 December 2022 | |
Class | Options |
Number acquired | Indirect - Dalroar Pty Ltd (MacLeman |
Investment Trust) | |
450,000 Options at $0.225 ea; vesting | |
225,000 16 November 2022 & 225,000 16 | |
November 2023; expire 14 November 2025 | |
Number disposed | Nil |
Value/Consideration | Nil |
Note: If consideration is non-cash, provide details and estimated | |
valuation | |
- See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1
For personal use only
Appendix 3Y
Change of Director's Interest Notice
No. of securities held after change | Indirect - Dalroar Pty Ltd (MacLeman |
Investment Trust) 78,069 Ordinary Shares; | |
122,548 Options with an exercise price of | |
$0.2476 and expire on 3 December 2022 | |
& 450,000 Options at $0.225 ea; vesting | |
225,000 16 November 2022 & 225,000 16 | |
November 2023; expire 14 November 2025 | |
Nature of change | |
Example: on-market trade, off-market trade, exercise of options, | The issued Options were approved by |
issue of securities under dividend reinvestment plan, participation in | |
Shareholders at the Annual General Meeting | |
buy-back | |
held on 16 November 2021 | |
Part 2 - Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract | Nil |
Nature of interest | |
Name of registered holder | |
(if issued securities) | |
Date of change | |
No. and class of securities to which | |
interest related prior to change | |
Note: Details are only required for a contract in | |
relation to which the interest has changed | |
Interest acquired | |
Interest disposed | |
Value/Consideration | |
Note: If consideration is non-cash, provide details | |
and an estimated valuation | |
Interest after change | |
Part 3 - +Closed period
Were the interests in the securities or contracts detailed N/A above traded during a +closed period where prior written clearance was required?
If so, was prior written clearance provided to allow the trade N/A to proceed during this period?
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 | 01/01/2011 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Anatara Lifesciences Ltd. published this content on 13 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 December 2021 01:45:01 UTC.